Recorlev® (levoketoconazole) – New orphan drug approval
On December 30, 2021, Xeris Biopharma announced the FDA approval of Recorlev (levoketoconazole), for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Top